Experimental designs for small randomised clinical trials: an algorithm for choice.
about
Mitochondrial disorders in children: toward development of small-molecule treatment strategiesSystematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditionsAggregated N-of-1 trials for unlicensed medicines for small populations: an assessment of a trial with ephedrine for myasthenia gravis.Clinical Trials in Veterinary Medicine: A New Era Brings New Challenges.A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov.A methodological framework for drug development in rare diseases.Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation.Directions for new developments on statistical design and analysis of small population group trialsDrugs Against Rare Diseases: Are The Regulatory Standards Higher?Challenges in orphan drug development and regulatory policy in China.Innovative research methods for studying treatments for rare diseases: methodological review.Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs.Optimizing drug development in oncology by clinical trial simulation: Why and how?Protocol for a systematic review of N-of-1 trial protocol guidelines and protocol reporting guidelines.Good-quality research in rare diseases: trials and tribulations.Mathematical model of T-cell lymphoblastic lymphoma: disease, treatment, cure or relapse of a virtual cohort of patients.Critical appraisal of arguments for the delayed-start design proposed as alternative to the parallel-group randomized clinical trial design in the field of rare disease.A framework: make it useful to guide and improve practice of clinical trial design in smaller populations.A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome?Executive Summary of the NHLBI Workshop Report: Leveraging Current Scientific Advancements to Understand Sarcoidosis Variability and Improve Outcomes.Establishing core outcome sets for phenylketonuria (PKU) and medium-chain Acyl-CoA dehydrogenase (MCAD) deficiency in children: study protocol for systematic reviews and Delphi surveys.Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French medical pharmacology.An overview of the impact of rare disease characteristics on research methodology.Not all that glitters is gold: A guide to the critical interpretation of drug trials in epilepsy.Lessons learned from IDeAl - 33 recommendations from the IDeAl-net about design and analysis of small population clinical trials.Using a meta-narrative literature review and focus groups with key stakeholders to identify perceived challenges and solutions for generating robust evidence on the effectiveness of treatments for rare diseases.Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIVApplicability and added value of novel methods to improve drug development in rare diseases
P2860
Q26767327-F7F52975-CE51-4016-98DF-B32A8478DF02Q28075766-3B665DC3-BC1E-4024-9E76-4F59DDFCFDEEQ30849110-2BDD7195-A707-493E-8F1F-36E5F1571B4EQ33900204-0948B778-C013-4F2E-9BED-24C44327EC1CQ34629984-28921BDD-2206-46C6-A5CE-C8E471844997Q34632424-51D2AA51-5D71-41DB-95CC-DCCEF6563376Q35835153-D2E91B66-B858-4AB0-9F57-193CCE68EFD4Q37006526-2E15D021-9308-41D5-BC76-F5801138E4E9Q37404472-F9555FF1-51E4-4130-A4AD-5AD3E733F612Q37591486-6C6A6402-713E-4A14-9D8F-D056F5E5A242Q38271185-1B0D0BDF-79A3-4E5C-AD8C-43F5256596AAQ38611303-27152BD5-9E5C-40F9-B189-8195806FC82EQ38675644-9A7E62C5-AE52-40DE-8FF2-360994E6ECB3Q38692488-0993434B-EC54-4A86-A4F2-8A52CBF5D27DQ38713946-7929E223-E4AA-4925-A3A7-899883850E0EQ38771125-A18B04FC-77BA-461A-9895-A96FE97EBE77Q41438847-877D27F5-A75C-4314-9D80-6CE2BE6864CCQ42363435-1338C5D2-33B3-4A78-B32C-4809A83152CAQ47160419-801796B2-7969-4A24-9271-B0787B36A960Q47239296-4214C3BB-2298-47C6-87B0-31346728FD3DQ47281654-84E5E8E1-4038-4646-976B-292980A88B16Q47304122-CFEB6BCF-00CF-485D-BC22-689C66A47A21Q47558738-0968D8BA-9E39-421F-8F40-81514C790EC4Q53277220-431DAD17-8282-435A-A448-ABF2FACD15D5Q54941922-0C1817FA-3216-4CF5-8B12-E03A595BF2D0Q55457221-608AFAD1-75E1-4B3D-A401-6936CC408197Q56910418-95E87978-B4B3-4A23-A9FA-95D1E105924FQ59136188-0474E66C-B223-4688-96FD-22ABA9239AEF
P2860
Experimental designs for small randomised clinical trials: an algorithm for choice.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Experimental designs for small randomised clinical trials: an algorithm for choice.
@ast
Experimental designs for small randomised clinical trials: an algorithm for choice.
@en
type
label
Experimental designs for small randomised clinical trials: an algorithm for choice.
@ast
Experimental designs for small randomised clinical trials: an algorithm for choice.
@en
prefLabel
Experimental designs for small randomised clinical trials: an algorithm for choice.
@ast
Experimental designs for small randomised clinical trials: an algorithm for choice.
@en
P2093
P2860
P356
P1476
Experimental designs for small randomised clinical trials: an algorithm for choice.
@en
P2093
Agathe Bajard
Anna Rosati
Anne-Charlotte Castellan
Behrouz Kassai
Behrouz Kassaï
CRESim & Epi-CRESim Project Groups
Catherine Chiron
Catherine Cornu
Charlotte Castellan
Clément Ballot
P2860
P2888
P356
10.1186/1750-1172-8-48
P50
P577
2013-03-25T00:00:00Z
P5875
P6179
1004783600